Revance Therapeutics Stock News

Well-known investment advisor Ed Yardeni believes that U.S. stocks are poised to rally this year. Speaking to CNBC last week, Yardeni said that the banking mini-crisis will be “very well-contained�

Today, we take a deeper look at Revance Therapeutics, Inc., a developer of aesthetic products that is seeing rapid revenue growth. The company has potential catalysts on the horizon but is bumping up

Investors in Revance Therapeutics Inc. (NASDAQ: RVNC) shouldn't have much to frown about after the stock gapped up 54.34% on January 9, and built upon those gains in February.

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 AM ET Company Participants Jessica Serra – Head of Investor Relations and ESG Mark Foley – Chief E

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -75% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st

Does Revance Therapeutics, Inc. (RVNC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Fintel reports that Jpmorgan Chase & Co has filed a 13G/A form with the SEC disclosing ownership of 4.98MM shares of Revance Therapeutics Inc (RVNC).

In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB ) climbed 6% so far this year.

Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.

Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the

The global Botulinum Toxin market should reach $9.09 billion by 2029. Technically, Revance Therapeutics, Inc.'s DAXXIFY is the first time in over 30 years that a truly innovative neurotoxin has been b

FDA approval of DAXXIFY for the treatment of patients with glabellar (frown) lines already obtained by Revance Therapeutics, Inc. A competing drug by the name of BOTOX was estimated to have generated

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark Foley - Chief Executive

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -37.65% and 0.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th

Mid-cap stocks are a good choice for investors who are okay with relatively more volatility to get some extra returns.